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In our manuscript, trimethylamine N-oxide (TMAO), as the biomarker of focus, was 
analyzed retrospectively after previously understanding its prognostic ability in acute heart 
failure (1), and, we hypothesized that it might be prognostic for other acute cardiovascular 
conditions, namely acute myocardial infarction (MI). For this, we used a well-documented 
historical cohort that had been previously investigated for several biomarkers, including N-
terminal pro B-type natriuretic peptide (NT-proBNP), and therefore would allow for 
comparison of the predictive ability of TMAO to the previously investigated/established 
biomarkers (e.g. Proenkephalin) (2).   Previous analysis in this cohort has shown NT-proBNP 
to be a marker of adverse outcome when used alone (3) but not when combined with other 
contemporary markers (e.g. Proenkephalin) (2).  The plasma concentrations of NT-proBNP 
were measured within 12-24 months of sample collection using an in-house assay that has 
shown strong correlation with the Roche Diagnostics assay (r=0.90) (2).  
In response to the present inquiry, additional analyses of the available NT-proBNP 
data over different time-points (i.e. admission and discharge) were performed.    Circulating 
concentrations at admission were approximately 20% higher than at later time points [median 
(inter-quartile range) 1075 (324-2692) pmol/L vs 812 (259-2199) pmol/L, respectively]. To 
investigate the prognostic ability of NT-proBNP, we used fully-loaded Cox regression 
models including NT-proBNP, but excluding TMAO, which indicated that NT-proBNP 
concentrations at admission were not able to independently predict outcome at 6 months or 2 
years (P>0.1), with discharge samples prognostic at 6 months (P≤0.048) but not 2 years 
(P>0.1). These results are consistent with a previous report using this cohort (2).   
As described within the manuscript, the patients in our study were representative of a 
patient population treated with a prior more risk-averse approach to invasive 
revascularization procedures consistent with standard of care at the time. Statistical 
investigations were appropriately adjusted for the rates of revascularization. The mentioned 
  
manuscript by Heeschen et al. (4) used patients originating from the PRISM study, which 
also showed similar rates of revascularization at 30 days (26% versus 21%, respectively) (5). 
However, our cohort does reflect a much larger proportion of ST-elevated MI (47% versus 
7%, respectively) but, as we did with revascularization, we adjusted our analyses by 
including STEMI class in the regression statistics.  
In conclusion, plasma NT-proBNP concentrations in our cohort of acute MI patients 
were not able to independently predict outcome at 6 months or 2 years when included in a 
fully-loaded Cox regression model including the biomarker of focus, TMAO. Exclusion of 
TMAO allowed prognostic prediction of adverse outcome at 6 months, but only in samples 
collected at discharge. Alternative demographics were observed in comparison to a previous 
cohort and did not follow similar prognostic qualities to previous reports, although the 
shortest-term prediction we investigated was at 6 months, compared to previous investigation 
at 30 days (4). Despite discrepancies among cohorts, BNP measurements have been 
collectively shown to predict outcome in acute coronary syndrome investigations and remain 
an important aspect of clinical practice. 
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